YY1P2: A Potential Drug Target and Biomarker for Cancer (G647012)

Target Name: YY1P2

NCBI ID: G647012

YY1P2

Other Name(s): YY1 transcription factor pseudogene 2

YY1P2: A Potential Drug Target and Biomarker for Cancer

Abstract:
YY1P2, a pseudogene located in the Y-chromosome, has been identified as a potential drug target and biomarker for cancer. Its expression has been associated with the development and progression of various malignancies, including androgen-sensitive prostate cancer. YY1P2 has also been shown to play a role in cancer cell survival and has been identified as a potential biomarker for cancer diagnosis and prognosis. Further research is needed to fully understand the implications of YY1P2 as a drug target and biomarker for cancer.

Introduction:
Cancer is a leading cause of death worldwide and is a significant economic burden on healthcare systems. The development and progression of cancer is a complex process that is influenced by multiple factors, including genetic and epigenetic modifications. Y-chromosome genes have been implicated in the development and progression of various malignancies, including androgen-sensitive prostate cancer. YY1P2, a pseudogene located in the Y-chromosome, has been identified as a potential drug target and biomarker for cancer.

Expression of YY1P2 and its association with cancer:
YY1P2 has been shown to be expressed in various tissues and tissues, including prostate, testes, lung, and colon. It has also been associated with the development and progression of various malignancies, including androgen-sensitive prostate cancer. In androgen-sensitive prostate cancer , high levels of YY1P2 have been shown to promote cancer cell survival and proliferation.

YY1P2 as a drug target:
YY1P2 has been identified as a potential drug target for cancer due to its involvement in cancer cell survival and proliferation. Its expression has been shown to promote the growth and survival of various cancer cell types, including androgen-sensitive prostate cancer cells. YY1P2 has also has been shown to play a role in the development of resistance to chemotherapy in cancer cells. Therefore, targeting YY1P2 as a drug target may be an effective way to treat cancer.

YY1P2 as a biomarker:
YY1P2 has also been identified as a potential biomarker for cancer due to its expression in various tissues and its association with the development and progression of cancer. Its high expression levels have been shown to be associated with poor prognosis in various malignancies, including androgen-sensitive prostate cancer. Therefore, measuring the expression of YY1P2 may be an effective way to diagnose and prognose cancer.

Conclusion:
YY1P2 has been identified as a potential drug target and biomarker for cancer. Its expression has been associated with the development and progression of various malignancies, including androgen-sensitive prostate cancer. Further research is needed to fully understand the implications of YY1P2 as a drug target and biomarker for cancer.

Protein Name: YY1 Transcription Factor Pseudogene 2

The "YY1P2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about YY1P2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets